

CONFIDENTIAL – INTERNAL USE ONLY

Document ID: AG-CORP-2025-001

Date: January 10, 2025

Department: Corporate Strategy & Investor Relations

Subject: AstraGen Pharmaceuticals – Corporate Profile & FY25 Strategic Vision

1. Executive Summary

AstraGen Pharmaceuticals is a leading multinational generic pharmaceutical company headquartered in Bridgewater, New Jersey, with a robust manufacturing footprint in India (Baddi, Hyderabad) and Ireland (Cork).

Mission: To democratize access to high-quality medication while pivoting towards value-added generics (VAG) and 505(b)(2) innovation pathways.

2. Core Capabilities

- **API Manufacturing:** High-volume fermentation and chemical synthesis capabilities. Largest global capacity for Tetracycline-class antibiotics.
- **Formulation:** Specialized in Oral Solid Dosage (OSD), with emerging capabilities in modified-release (MR) technologies and topical delivery systems.
- **Global Supply Chain:** Distribution network covering North America (60% revenue), EU (25%), and Emerging Markets (15%).

3. Therapeutic Focus Areas

1. **Dermatology:** Market leader in acne and rosacea generics.
2. **Cardiovascular:** Strong portfolio of anti-hypertensives (Sartans).
3. **Anti-Infectives:** Legacy portfolio of broad-spectrum antibiotics.
4. **CNS (Central Nervous System):** *Strategic Growth Priority for 2026.*

4. FY25 Strategic Imperatives ("Project Horizon")

The generics market is facing intense price erosion (approx. 8% YoY). To sustain EBITDA margins, AstraGen must:

- **Diversify:** Move beyond "vanilla generics" into complex generics.
- **Repurpose:** Utilize existing API surpluses to find new indications (Drug Repurposing) to reduce R&D timelines from 10 years to 3-4 years.

- **Optimize:** Digitize the R&D workflow using Agentic AI to scan for opportunities.

5. Financial Snapshot (FY24)

- **Global Revenue:** \$4.2 Billion
- **R&D Spend:** \$320 Million (7.6% of sales)
- **Top Selling Assets:** TelmiGuard (Telmisartan), MinoClear (Minocycline), DermSoothe (Clobetasol).

WARNING: This document contains proprietary information. Unauthorized distribution is a violation of company policy.